These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15787285)

  • 1. [Will the mystery of Parkinson's disease be resolved?].
    Lyytinen J; Kaakkola S
    Duodecim; 2005; 121(3):275-84. PubMed ID: 15787285
    [No Abstract]   [Full Text] [Related]  

  • 2. [ Is Parkinson's disease due to deficiency of dopamine?].
    Castrén E
    Duodecim; 2005; 121(7):782-3; author reply 783-4. PubMed ID: 15909967
    [No Abstract]   [Full Text] [Related]  

  • 3. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional neuroanatomy of the basal ganglia in Parkinson's disease.
    Wichmann T; DeLong MR
    Adv Neurol; 2003; 91():9-18. PubMed ID: 12442660
    [No Abstract]   [Full Text] [Related]  

  • 5. Estrogen and Parkinson's disease.
    Horstink MW; Strijks E; Dluzen DE
    Adv Neurol; 2003; 91():107-14. PubMed ID: 12442669
    [No Abstract]   [Full Text] [Related]  

  • 6. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease.
    Lang AE; Obeso JA
    Ann Neurol; 2004 Jun; 55(6):761-5. PubMed ID: 15174009
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitamin D and Parkinson's disease--a hypothesis.
    Newmark HL; Newmark J
    Mov Disord; 2007 Mar; 22(4):461-8. PubMed ID: 17230473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease and cancer: insights for pathogenesis from epidemiology .
    D'Amelio M; Ragonese P; Sconzo G; Aridon P; Savettieri G
    Ann N Y Acad Sci; 2009 Feb; 1155():324-34. PubMed ID: 19250224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL; Kelly AM; Kennedy GA
    Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does Parkinson's disease begin? The role of compensatory mechanisms.
    Obeso JA; Rodriguez-Oroz MC; Lanciego JL; Rodriguez Diaz M
    Trends Neurosci; 2004 Mar; 27(3):125-7; author reply 127-8. PubMed ID: 15036875
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
    Wang S; Qi XJ; Han D
    Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
    Paillé V; Henry V; Lescaudron L; Brachet P; Damier P
    Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-amplification of nigral degeneration in Parkinson's disease: a hypothesis.
    Ionov ID
    Int J Neurosci; 2008 Dec; 118(12):1763-80. PubMed ID: 18937118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
    Kovacs GG; Milenkovic IJ; Preusser M; Budka H
    Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine and adult neurogenesis.
    Borta A; Höglinger GU
    J Neurochem; 2007 Feb; 100(3):587-95. PubMed ID: 17101030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of lipid peroxides in patients with Parkinson's disease.
    Sanyal J; Bandyopadhyay SK; Banerjee TK; Mukherjee SC; Chakraborty DP; Ray BC; Rao VR
    Eur Rev Med Pharmacol Sci; 2009; 13(2):129-32. PubMed ID: 19499848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autonomic dysfunction in RBD--what can it teach us about disease progression?
    Postuma RB; Gagnon JF; Montplaisir J
    Sleep Med; 2008 Jul; 9(5):473-4. PubMed ID: 18024175
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.